| ADMIN | STUDY | CLOSE DATE |
Intergroup Study |
OPEN | COOPGRP | COUNT |
|---|---|---|---|---|---|---|
| BREAST | S2007-Breast, Brain Mets, Sacituzumab Govitecan | 07-APR-25 | N | ALLIANCE | 7 | |
| ECOG-ACRIN | 3 | |||||
| SWOG | 18 | |||||
| sum | 28 | |||||
| S2206-Brst, Stg II-III, MP2, Neoadj Chemo +/- Durva | Y | ALLIANCE | 35 | |||
| ECOG-ACRIN | 40 | |||||
| NRG | 29 | |||||
| SWOG | 132 | |||||
| sum | 236 | |||||
| S2212-Breast, TNBC, Neoadj Chemo + Pembro | Y | ALLIANCE | 172 | |||
| ECOG-ACRIN | 139 | |||||
| NRG | 103 | |||||
| SWOG | 481 | |||||
| sum | 895 | |||||
| CCD | S1703-Met Breast, STM-monitoring v Usual Care | Y | ALLIANCE | 20 | ||
| ECOG-ACRIN | 31 | |||||
| NRG | 21 | |||||
| SWOG | 356 | |||||
| sum | 428 | |||||
| ERLYTX | EAY191-S3-ComboMATCH: Adv Solid Tumors, Pac+Ipatasertib | Y | ALLIANCE | 6 | ||
| ECOG-ACRIN | 9 | |||||
| NRG | 9 | |||||
| SWOG | 8 | |||||
| sum | 32 | |||||
| S2012-Extrapulm NEC, Stg IV, Combo Chemo +/- Atezo | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 12 | |||||
| NRG | 10 | |||||
| SWOG | 79 | |||||
| sum | 119 | |||||
| GI | S1922-Small Bowel,Ram+Pac vs FOLFIRI, mets/unresect | Y | ALLIANCE | 12 | ||
| ECOG-ACRIN | 3 | |||||
| NRG | 3 | |||||
| SWOG | 26 | |||||
| sum | 44 | |||||
| S2001-Rando II, Mets Pancreas , BRCA1/2, Comb Chemo | T | ALLIANCE | 8 | |||
| ECOG-ACRIN | 16 | |||||
| NRG | 9 | |||||
| SWOG | 40 | |||||
| sum | 73 | |||||
| S2104-Panc,Resect High-risk,Postop Adj Chemo vs Obs | Y | ALLIANCE | 11 | |||
| ECOG-ACRIN | 9 | |||||
| NRG | 8 | |||||
| SWOG | 52 | |||||
| sum | 80 | |||||
| S2303-Gas/Esoph/GEJ, Adv, Ram + Pac +/- Nivo | Y | ALLIANCE | 18 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 4 | |||||
| SWOG | 27 | |||||
| sum | 52 | |||||
| GU | S1802-Pros, Stg IV, SST ± Surg/RT to Primary Tum | Y | ALLIANCE | 118 | ||
| ECOG-ACRIN | 104 | |||||
| NRG | 115 | |||||
| SWOG | 619 | |||||
| sum | 956 | |||||
| S1931-RENAL, Stg IV, IO + Nephrectomy. vs IO Only | Y | ALLIANCE | 8 | |||
| ECOG-ACRIN | 16 | |||||
| NRG | 14 | |||||
| SWOG | 97 | |||||
| sum | 135 | |||||
| S1937-Blad, Mets, Eribulin + Gem vs SOC | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 18 | |||||
| NRG | 2 | |||||
| SWOG | 83 | |||||
| sum | 110 | |||||
| S2200-pRCC, Adv, Cabo ± Atezo | Y | ALLIANCE | 2 | |||
| ECOG-ACRIN | 6 | |||||
| NRG | 4 | |||||
| SWOG | 22 | |||||
| sum | 34 | |||||
| S2210-Pros, High Risk, BRCA, Neoadj Carbo | Y | SWOG | 5 | |||
| sum | 5 | |||||
| LEUK | MM1OA-S03-AML, Newly Dx, Ven+ASTX727 vs Ven+ASTX727+Ena | Y | ECOG-ACRIN | 3 | ||
| NRG | 1 | |||||
| SWOG | 2 | |||||
| sum | 6 | |||||
| MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental | Y | ALLIANCE | 7 | |||
| ECOG-ACRIN | 10 | |||||
| NRG | 1 | |||||
| SWOG | 25 | |||||
| sum | 43 | |||||
| MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials | Y | ALLIANCE | 168 | |||
| CCTG | 47 | |||||
| ECOG-ACRIN | 155 | |||||
| NRG | 26 | |||||
| SWOG | 314 | |||||
| sum | 710 | |||||
| S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 | Y | ALLIANCE | 2 | |||
| COG | 1 | |||||
| ECOG-ACRIN | 2 | |||||
| SWOG | 19 | |||||
| sum | 24 | |||||
| S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O | Y | ALLIANCE | 42 | |||
| CCTG | 12 | |||||
| ECOG-ACRIN | 18 | |||||
| NRG | 5 | |||||
| SWOG | 80 | |||||
| sum | 157 | |||||
| LUNG | LUNGMAP-NSCLC, Adv, Master | Y | ALLIANCE | 901 | ||
| ECOG-ACRIN | 371 | |||||
| NRG | 511 | |||||
| SWOG | 1970 | |||||
| sum | 3753 | |||||
| S1800E-Non-Match: Docetaxel + Ramu +/- Cemiplimab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 2 | |||||
| SWOG | 17 | |||||
| sum | 25 | |||||
| S1827-SCLC, MRI Surveillance +/- PCI | Y | ALLIANCE | 26 | |||
| CCTG | 38 | |||||
| ECOG-ACRIN | 11 | |||||
| NRG | 86 | |||||
| SWOG | 133 | |||||
| sum | 294 | |||||
| S1900G-EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu | Y | ALLIANCE | 3 | |||
| NRG | 3 | |||||
| SWOG | 16 | |||||
| sum | 22 | |||||
| S1900J-MET Amplification: Amivantamab Hyaluronidase | Y | ALLIANCE | 1 | |||
| SWOG | 1 | |||||
| sum | 2 | |||||
| S1900K-MET Exon 14: Tepotinib +/- Ramucirumab | Y | ALLIANCE | 4 | |||
| ECOG-ACRIN | 4 | |||||
| SWOG | 6 | |||||
| sum | 14 | |||||
| S1933-NSCLC, Stg II-III, RT + Atezo | Y | ALLIANCE | 5 | |||
| NRG | 2 | |||||
| SWOG | 40 | |||||
| sum | 47 | |||||
| S2414-NSCLC, Stg II-IIIB, Durva vs Surveillance | Y | SWOG | 3 | |||
| sum | 3 | |||||
| LYMPH | S2114-NHL, Rel/Ref, CD19 CAR-T +/- Consolidation | Y | ALLIANCE | 44 | ||
| ECOG-ACRIN | 10 | |||||
| NRG | 6 | |||||
| SWOG | 97 | |||||
| sum | 157 | |||||
| S2207-LBCL, Transplant Inelig, Targeted Tx + Tafa | Y | ALLIANCE | 6 | |||
| NRG | 4 | |||||
| SWOG | 21 | |||||
| sum | 31 | |||||
| S2308-FL, LTB, Mosunetuzumab vs Rituximab | Y | ALLIANCE | 42 | |||
| ECOG-ACRIN | 24 | |||||
| NRG | 9 | |||||
| SWOG | 110 | |||||
| sum | 185 | |||||
| MMYEL | S1803-MM, Maintenance, Len vs Len/Dara | Y | ALLIANCE | 226 | ||
| CCTG | 21 | |||||
| ECOG-ACRIN | 188 | |||||
| NRG | 117 | |||||
| SWOG | 786 | |||||
| sum | 1338 | |||||
| S2005-WM, Prev. Untreated, I/R +/- Venetoclax | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 1 | |||||
| SWOG | 4 | |||||
| sum | 19 | |||||
| S2209-MM, Newly Dx, VRd-R->R v DRd-R->R v DRD-DR->D | Y | ALLIANCE | 11 | |||
| ECOG-ACRIN | 8 | |||||
| NRG | 5 | |||||
| SWOG | 75 | |||||
| sum | 99 | |||||
| S2213-AL Amyloidosis, Newly Dx, Dara-VCD v ASCT | Y | ALLIANCE | 3 | |||
| ECOG-ACRIN | 2 | |||||
| NRG | 1 | |||||
| SWOG | 17 | |||||
| sum | 23 | |||||
| MULT | S2101-Melan or HNSCC, Adv, Cabo + Nivo | Y | ALLIANCE | 9 | ||
| ECOG-ACRIN | 7 | |||||
| NRG | 6 | |||||
| SWOG | 36 | |||||
| sum | 58 | |||||
| PEOLC | S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol | Y | ECOG-ACRIN | 43 | ||
| SWOG | 263 | |||||
| S1501 | Y | ALLIANCE | 37 | |||
| NRG | 30 | |||||
| sum | 373 | |||||
| S2408-Panc Fistula Prevention, Lanreotide | Y | ALLIANCE | 1 | |||
| ECOG-ACRIN | 3 | |||||
| NRG | 2 | |||||
| SWOG | 13 | |||||
| sum | 19 | |||||
| SXQOL | S2013-I-CHECKIT: ICI toxicity risk prediction study | Y | ALLIANCE | 365 | ||
| ECOG-ACRIN | 121 | |||||
| NRG | 273 | |||||
| SWOG | 1528 | |||||
| sum | 2287 | |||||
| S2205-ICE COMPRESS: Reduction of CIPN from Taxanes | Y | ALLIANCE | 71 | |||
| ECOG-ACRIN | 11 | |||||
| NRG | 121 | |||||
| SWOG | 252 | |||||
| sum | 455 | |||||